Transfection of PDCD5 sensitizes colorectal cancer cells to cisplatin-induced apoptosis in vitro and in vivo

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 120-126

  Yin, Anning ^a   Jiang, Yingan ^a   Zhang, Xianfeng ^a   Zhao, Juan ^a   Luo, Hesheng ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cisplatin; Colorectal cancer; Programmed Cell Death 5 (PDCD5)

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PROGRAMMED CELL DEATH 5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL LABELING; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIZATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STABLE TRANSFECTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78049288176     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.040     Document Type: Article

References (37)

1. Chen Y., Douglass T., Jeffes E.W., Xu Q., Williams C.C., Arpajirakul N., Delgado C., Kleinman M., Sanchez R., Dan Q., et al. Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a "paraptosis"-induced pathway that promotes systemic immunity against intracranial T9 gliomas. Blood 2002, 100:1373-1380.
2. Chen L.N., Wang Y., Ma D.L., Chen Y.Y. Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression. Apoptosis 2006, 11:101-111.
3. Chen C., Zhou H., Xu L., Xu D., Wang Y., Zhang Y., Liu X., Liu Z., Ma D., Ma Q., et al. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo. Apoptosis 2010, 15:805-813.
4. Choi E.A., Lei H., Maron D.J., Mick R., Barsoum J., Yu Q.C., Fraker D.L., Wilson J.M., Spitz F.R. Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. Clin. Cancer Res. 2004, 10:1535-1544.
5. Cohen S.M., Lippard S.J. Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 2001, 67:93-130.
6. Dal Canto M.C., Gurney M.E. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am. J. Pathol. 1994, 145:1271-1279.
7. Dong F., Wang L., Davis J.J., Hu W., Zhang L., Guo W., Teraishi F., Ji L., Fang B. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin. Cancer Res. 2006, 12:5224-5230.
8. Durai R., Yang S.Y., Seifalian A.M., Winslet M.C. Principles and applications of gene therapy in colon cancer. J. Gastrointestin. Liver Dis. 2008, 17:59-67.
9. Etzioni D.A., El-Khoueiry A.B., Beart R.W. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer 2008, 113:3279-3289.
10. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5:876-885.
11. Hedenfalk I., Duggan D., Chen Y., Radmacher M., Bittner M., Simon R., Meltzer P., Gusterson B., Esteller M., Kallioniemi O.P., et al. Gene-expression profiles in hereditary breast cancer. N Engl J. Med. 2001, 344:539-548.
12. Jean G.W., Shah S.R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008, 28:742-754.
13. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
14. Kohne C.H., Lenz H.J. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009, 14:478-488.
15. Li H., Wang Q., Gao F., Zhu F., Wang X., Zhou C., Liu C., Chen Y., Ma C., Sun W., et al. Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas. Oncol. Rep. 2008, 20:573-579.
16. Lim Y.J., Rhee J.C., Bae Y.M., Chun W.J. Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. World J. Gastroenterol. 2007, 13:1947-1952.
17. Lin X., Howell S.B. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol. Cancer Ther. 2006, 5:1239-1247.
18. Lipinski K.S., Djeha A.H., Ismail T., Mountain A., Young L.S., Wrighton C.J. High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol. Ther. 2001, 4:365-371.
19. Liu H., Wang Y., Zhang Y., Song Q., Di C., Chen G., Tang J., Ma D. TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem. Biophys. Res. Commun. 1999, 254:203-210.
20. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
21. Meyn R.E., Stephens L.C., Hunter N.R., Milas L. Kinetics of cisplatin-induced apoptosis in murine mammary and ovarian adenocarcinomas. Int. J. Cancer 1995, 60:725-729.
22. Omura K. Advances in chemotherapy against advanced or metastatic colorectal cancer. Digestion 2008, 77(Suppl 1):13-22.
23. Oyama K., Shiota G., Ito H., Murawaki Y., Kawasaki H. Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats. Carcinogenesis 2002, 23:885-892.
24. Rosse T., Olivier R., Monney L., Rager M., Conus S., Fellay I., Jansen B., Borner C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 1998, 391:496-499.
25. Ruan G.R., Qin Y.Z., Chen S.S., Li J.L., Ma X., Chang Y., Wang Y.Z., Fu J.Y., Liu Y.R. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. Leuk. Res. 2006, 30:1159-1165.
26. Rui M., Chen Y., Zhang Y., Ma D. Transfer of anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation can inhibit the apoptosis. Life Sci. 2002, 71:1771-1778.
27. Sabaawy H.E., Farley T., Ahmed T., Feldman E., Abraham N.G. Synergetic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol. 1999, 101:82-88.
28. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
29. Sorenson C.M., Barry M.A., Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl Cancer Inst. 1990, 82:749-755.
30. Spinola M., Meyer P., Kammerer S., Falvella F.S., Boettger M.B., Hoyal C.R., Pignatiello C., Fischer R., Roth R.B., Pastorino U., et al. Association of the PDCD5 locus with lung cancer risk and prognosis in smokers. J. Clin. Oncol. 2006, 24:1672-1678.
31. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., Erdkamp F.L., Vos A.H., van Groeningen C.J., Sinnige H.A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J. Med. 2009, 360:563-572.
32. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., Pinter T., Lim R., Bodoky G., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J. Med. 2009, 360:1408-1417.
33. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4:307-320.
34. Wang Y., Li X., Wang L., Ding P., Zhang Y., Han W., Ma D. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J. Cell Sci. 2004, 117:1525-1532.
35. Wolpin B.M., Mayer R.J. Systemic treatment of colorectal cancer. Gastroenterology 2008, 134:1296-1310.
36. Xu X.R., Huang J., Xu Z.G., Qian B.Z., Zhu Z.D., Yan Q., Cai T., Zhang X., Xiao H.S., Qu J., et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc. Natl Acad. Sci. U. S. A. 2001, 98:15089-15094.
37. Yang Y.H., Zhao M., Li W.M., Lu Y.Y., Chen Y.Y., Kang B. Expression of programmed cell death 5 gene involves in regulation of apoptosis in gastric tumor cells. Apoptosis 2006, 11:993-1001.